Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications

PLoS ONE

Volumn 6, Issue 4, 2011, Pages

  Guan, Ruili ^a,b,c   Purohit, Sharad ^c,d   Wang, Hongjie ^c   Bode, Bruce ^e   Reed, John Chip ^f   Steed, R Dennis ^f   Anderson, Stephen W ^g   Steed, Leigh ^c   Hopkins, Diane ^c   Xia, Chun ^b,c   She, Jin Xiong ^c,d  

^a NANJING TECH UNIVERSITY   (China)

^b CHINA AGRICULTURAL UNIVERSITY   (China)

^c GENERAL ELECTRIC COMPANY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e ATLANTA DIABETES ASSOCIATES   (United States)

^f Southeastern Endocrine and Diabetes   (United States)

^g Pediatric Endocrine Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; MACROPHAGE DERIVED CHEMOKINE; CCL2 PROTEIN, HUMAN; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AMPUTATION; ARTICLE; BLINDNESS; CHILD; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC NEPHROPATHY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; GENOTYPE; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INFANT; INSULIN DEPENDENT DIABETES MELLITUS; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; PERIPHERAL NEUROPATHY; PRESCHOOL CHILD; PROMOTER REGION; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SERUM; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CASE CONTROL STUDY; GENETICS; POLYMERASE CHAIN REACTION;

CASE-CONTROL STUDIES; CHEMOKINE CCL2; DIABETES MELLITUS, TYPE 1; GENOTYPE; HUMANS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 79954521692     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017822     Document Type: Article

References (37)

1. Martinovic I, Abegunewardene N, Seul M, Vosseler M, Horstick G, et al. (2005) Elevated monocyte chemoattractant protein-1 serum levels in patients at risk for coronary artery disease. Circ J 69: 1484-1489.
2. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, et al. (2009) CXCL10 and CCL2 serum levels in patients with mixed cryoglobulinaemia and hepatitis C. Dig Liver Dis 41: 42-48.
3. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, et al. (2009) CXCL10 and CCL2 chemokine serum levels in patients with hepatitis C associated with autoimmune thyroiditis. J Interferon Cytokine Res 29: 345-351.
4. Antonelli A, Fallahi P, Delle SA, Ferrari SM, Maccheroni M, et al. (2009) High values of Th1 (CXCL10) and Th2 (CCL2) chemokines in patients with psoriatic arthtritis. Clin Exp Rheumatol 27: 22-27.
5. Antonelli A, Fallahi P, Delle SA, Ferrari SM, Maccheroni M, et al. (2008) High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 41: 537-542.
6. Antonelli A, Ferri C, Fallahi P, Colaci M, Giuggioli D, et al. (2008) Th1 and Th2 chemokine serum levels in systemic sclerosis in the presence or absence of autoimmune thyroiditis. J Rheumatol 35: 1809-1811.
7. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Frascerra S, et al. (2008) Alpha-chemokine CXCL10 and beta-chemokine CCL2 serum levels in patients with hepatitis C-associated cryoglobulinemia in the presence or absence of autoimmune thyroiditis. Metabolism 57: 1270-1277.
8. Antonelli A, Ferri C, Fallahi P, Ferrari SM, Giuggioli D, et al. (2008) CXCL10 (alpha) and CCL2 (beta) chemokines in systemic sclerosis-a longitudinal study. Rheumatology (Oxford) 47: 45-49.
9. Kim CS, Park HS, Kawada T, Kim JH, Lim D, et al. (2006) Circulating levels of MCP-1 and IL-8 are elevated in human obese subjects and associated with obesity-related parameters. Int J Obes (Lond) 30: 1347-1355.
10. Kokkotou E, Marafelia P, Mantzos EI, Tritos NA, (2002) Serum monocyte chemoattractant protein-1 is increased in chronic autoimmune thyroiditis. Metabolism 51: 1489-1493.
11. Mazur G, Wrobel T, Butrym A, Kapelko-Slowik K, Poreba R, et al. (2007) Increased monocyte chemoattractant protein 1 (MCP-1/CCL-2) serum level in acute myeloid leukemia. Neoplasma 54: 285-289.
12. Stankovic A, Slavic V, Stamenkovic B, Kamenov B, Bojanovic M, et al. (2009) Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity. Bratisl Lek Listy 110: 641-646.
13. Gu L, Tseng S, Horner RM, Tam C, Loda M, et al. (2000) Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 404: 407-411.
14. Scarpini E, Galimberti D, Baron P, Clerici R, Ronzoni M, et al. (2002) IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease. J Neurol Sci 195: 41-46.
15. Antonelli A, Fallahi P, Ferrari SM, Pupilli C, d'Annunzio G, et al. (2008) Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med 25: 1349-1353.
16. Kiyici S, Erturk E, Budak F, Ersoy C, Tuncel E, et al. (2006) Serum monocyte chemoattractant protein-1 and monocyte adhesion molecules in type 1 diabetic patients with nephropathy. Arch Med Res 37: 998-1003.
17. Zineh I, Beitelshees AL, Silverstein JH, Haller MJ, (2009) Serum monocyte chemoattractant protein-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. Diabetes Care 32: 465-467.
18. Hanifi-Moghaddam P, Kappler S, Seissler J, Muller-Scholze S, Martin S, et al. (2006) Altered chemokine levels in individuals at risk of Type-1 diabetes mellitus. Diabetic Medicine 23: 156-163.
19. Palmieri O, Latiano A, Salvatori E, Valvano MR, Bossa F, et al. (2010) The -A2518G Polymorphism of Monocyte Chemoattractant Protein-1 Is Associated With Crohn's Disease. Am J Gastroenterol 105: 1586-1594.
20. Radstake TRDJ, Vonk MC, Dekkers M, Schijvenaars MMVA, Treppichio WL, et al. (2009) The -2518A/G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. Human Immunology 70: 130-133.
21. Park HJ, Yoon SH, Zheng LT, Lee KH, Kim JW, et al. (2007) Association of the -2510A/G chemokine (C-C motif) ligand-2 polymorphism with knee osteoarthritis in a Korean population. Scand J Rheumatol 36: 299-306.
22. Guerra SD, D'A V, Gualtierotti G, Filipponi F, Boggi U, Simone PD, et al. (2010) A Common Polymorphism in the Monocyte Chemoattractant Protein-1 (MCP-1) Gene Regulatory Region Influences MCP-1 Expression and Function of Isolated Human Pancreatic Islets. Transplant Proc 42: 2247-2249.
23. Rovin BH, Lu L, Saxena R, (1999) A Novel Polymorphism in the MCP-1 Gene Regulatory Region That Influences MCP-1 Expression. Biochemical and Biophysical Research Communications 259: 344-348.
24. Georgios IP, David AS, Haritha A, Janette L, Anna L, et al. (2005) Is the Monocyte Chemotactic Protein-1 -2518 G Allele a Risk Factor for Severe Acute Pancreatitis? Clin Gastroenterol Hepatol 3: 475-481.
25. Tesch GH, (2008) MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. American Journal of Physiology- Renal Physiology 294: F697-F701.
26. Tarabra E, Giunti S, Barutta F, Salvidio G, Burt D, et al. (2009) Effect of the Monocyte Chemoattractant Protein-1/CC Chemokine Receptor 2 System on Nephrin Expression in Streptozotocin-Treated Mice and Human Cultured Podocytes. Diabetes 58: 2109-2118.
27. Mao Z, Shandong Y, Zhimin Z, Yan C, Xiucai L, et al. (2009) Rosiglitazone protects diabetic rats against kidney disease through the suppression of renal moncyte chemoattractant protein-1 expression. J Diabetes Complications 23: 124-129.
28. Kanamori H, Matsubara T, Mima A, Sumi E, Nagai K, et al. (2007) Inhibition of MCP-1/CCR2 pathway ameliorates the development of diabetic nephropathy. Biochemical and Biophysical Research Communications 360: 772-777.
29. Harsimran K, Singh AAP, Guruvinder S, Sharda S, Vasudha S, (2009) Plasma monocyte chemoattractant protein-1 as risk marker in type 2 diabetes mellitus and coronary artery disease in North Indians. Diabetes and Vascular Disease Research 6: 288-290.
30. Piemonti L, Calori G, Lattuada G, Mercalli A, Ragogna F, et al. (2009) Association Between Plasma Monocyte Chemoattractant Protein-1 Concentration and Cardiovascular Disease Mortality in Middle-Aged Diabetic and Nondiabetic Individuals. Diabetes Care 32: 2105-2110.
31. Gu L, Rutledge B, Fiorillo J, Ernst C, Grewal I, et al. (1997) In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 62: 577-580.
32. Sia C, (2005) Imbalance in Th cell polarization and its relevance in type 1 diabetes mellitus. Rev Diabet Stud 2: 182-186.
33. Berman MA, Sandborg CI, Wang Z, Imfeld KL, Zaldivar F Jr, et al. (1996) Decreased IL-4 production in new onset type I insulin-dependent diabetes mellitus. J Immunol 157: 4690-4696.
34. Mueller R, Krahl T, Sarvetnick N, (1996) Pancreatic expression of interleukin-4 abrogates insulitis and autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 184: 1093-1099.
35. Rollins BJ, Pober JS, (1991) Interleukin-4 induces the synthesis and secretion of MCP-1/JE by human endothelial cells. Am J Pathol 138: 1315-1319.
36. R Development Core Team (2010) R: A language and environment for statistical computing Vienna, Austria R Foundation for Statistical Computing.
37. Liu S, Wang H, Jin Y, Podolsky R, Reddy MV, et al. (2009) IFIH1 polymorphisms are significantly associated with type 1 diabetes and IFIH1 gene expression in peripheral blood mononuclear cells. Hum Mol Genet 18: 358-365.